AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20506712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 20506712 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Lactobacillus colonization
Number of subjects: 150
Study 20506712 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison among three groups
Number of subjects: 150
Study 18555732 — intervention group
Group type: EXPERIMENTAL
Intervention: Various diagnostic labels for shoulder pain
Number of subjects: 0
Study 18555732 — intervention group
Group type: EXPERIMENTAL
Intervention: Abolishing the use of diagnostic labels
Number of subjects: 0
Study 15701355 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression
Number of subjects: 0
Study 15701355 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based strategy
Number of subjects: 0
Study 15701355 — intervention group
Group type: COMPARATOR
Intervention: Monitor-only group
Number of subjects: 0
Study 11939435 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline 0.05 microg/kg
Number of subjects: 0
Study 11939435 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline 0.075 microg/kg
Number of subjects: 0
Study 11939435 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline 0.5 microg/kg
Number of subjects: 0
Study 11939435 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (both doses)
Number of subjects: 0
Study 10369554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG hyperthermia therapy
Number of subjects: 50
Study 10369554 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 50
Study 7552586 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified zinc oxide fume exposure
Number of subjects: 14
Study 7552586 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 14
Study 2248080 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 28
Study 2248080 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 31693683 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity (LPA)
Number of subjects: 385
Study 31693683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior patterns
Number of subjects: 385
Study 31693683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time and bout length
Number of subjects: 385
Study 31693683 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 385
Study 31693683 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a student
Number of subjects: 385
Study 30333315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 75 mg by mouth 3 times daily for 4 months
Number of subjects: 55
Study 30333315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 30333315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 55
Study 27149048 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRVAMP (alternative process)
Number of subjects: 1412
Study 27149048 — intervention group
Group type: COMPARATOR
Intervention: MMRV (currently licensed)
Number of subjects: 1412
Study 27149048 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRVAMP
Number of subjects: 1412
Study 27149048 — intervention group
Group type: COMPARATOR
Intervention: MMRV
Number of subjects: 1412
Study 25264726 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS lobectomy (A)
Number of subjects: 32
Study 25264726 — intervention group
Group type: COMPARATOR
Intervention: Open resection (B)
Number of subjects: 32
Study 22438308 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronically monitored adherence
Number of subjects: 180
Study 22438308 — intervention group
Group type: EXPERIMENTAL
Intervention: Shea self-report adherence
Number of subjects: 180
Study 22438308 — intervention group
Group type: EXPERIMENTAL
Intervention: Days adherent
Number of subjects: 180
Study 22438308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervals adherent
Number of subjects: 180
Study 22438308 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitor
Number of subjects: 180
Study 22438308 — intervention group
Group type: EXPERIMENTAL
Intervention: Shea self-report
Number of subjects: 180
Study 22438308 — intervention group
Group type: EXPERIMENTAL
Intervention: Other measures
Number of subjects: 180
Study 20716712 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2 g/day)
Number of subjects: 36
Study 20716712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18676180 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 234
Study 18676180 — intervention group
Group type: COMPARATOR
Intervention: Telephone
Number of subjects: 234
Study 15807876 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.1 IU/kg/day [0.033 mg/kg/day]
Number of subjects: 30
Study 15807876 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.2 IU/kg/day [0.067 mg/kg/day]
Number of subjects: 30
Study 15807876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14632341 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg kg(‐1))
Number of subjects: 50
Study 14632341 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (5 mg kg(‐1))
Number of subjects: 50
Study 14632341 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 50
Study 14632341 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 50
Study 11515626 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain GG
Number of subjects: 25
Study 11515626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8874372 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (maximum daily dosage)
Number of subjects: 55
Study 8874372 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (maximum daily dosage)
Number of subjects: 55
Study 8874372 — intervention group
Group type: COMPARATOR
Intervention: First-generation sulfonylurea agents
Number of subjects: 55
Study 1531566 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 20
Study 6394020 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniocentesis group (N = 25)
Number of subjects: 47
Study 6394020 — intervention group
Group type: COMPARATOR
Intervention: No amniocentesis group (N = 22)
Number of subjects: 47
Study 31815640 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile Link - A theory-based messaging intervention
Number of subjects: 0
Study 31815640 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 30214718 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit with feedback and academic detailing
Number of subjects: 1802
Study 27370156 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable bladder scanner (BS)
Number of subjects: 22
Study 27370156 — intervention group
Group type: COMPARATOR
Intervention: Control group (CBCT only pre-RT)
Number of subjects: 22
Study 24977342 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 399
Study 24977342 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 399
Study 21914632 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized practice
Number of subjects: 0
Study 21914632 — intervention group
Group type: COMPARATOR
Intervention: Grouped practice
Number of subjects: 0
Study 19462524 — intervention group
Group type: EXPERIMENTAL
Intervention: IL1A+4845(*)TT genotype
Number of subjects: 532
Study 19462524 — intervention group
Group type: COMPARATOR
Intervention: Higher baseline CD4 T-cell counts
Number of subjects: 532
Study 19462524 — intervention group
Group type: COMPARATOR
Intervention: IL1A-889 and IL1A+4845 genotypes
Number of subjects: 532
Study 18186680 — intervention group
Group type: EXPERIMENTAL
Intervention: New ureteroscope (Flex‐X, Karl Storz)
Number of subjects: 32
Study 18186680 — intervention group
Group type: COMPARATOR
Intervention: Standard ureteroscope
Number of subjects: 32
Study 15727639 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT with 20 J cm(‐2)
Number of subjects: 29
Study 15727639 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT with 10 J cm(‐2)
Number of subjects: 29
Study 15727639 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT with 5 J cm(‐2)
Number of subjects: 29
Study 15727639 — intervention group
Group type: COMPARATOR
Intervention: Keratolytic pretreatment
Number of subjects: 29
Study 12486868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 14
Study 12486868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9653784 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews conducted by responsible caregivers
Number of subjects: 52
Study 9653784 — intervention group
Group type: COMPARATOR
Intervention: Interviews conducted by interviewers from other providers
Number of subjects: 52
Study 8587620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet
Number of subjects: 13
Study 8587620 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of sodium bicarbonate
Number of subjects: 13
Study 8587620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet in patients treated with tiopronin
Number of subjects: 13
Study 2650798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold and hydroxychloroquine
Number of subjects: 101
Study 2650798 — intervention group
Group type: COMPARATOR
Intervention: Gold and placebo
Number of subjects: 101
Study 1172599 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐acetyldigoxin tablets (Novodigal¿)
Number of subjects: 11
Study 1172599 — intervention group
Group type: EXPERIMENTAL
Intervention: PETN/beta‐acetyldigoxin tablets (Nitro‐Novodigal¿)
Number of subjects: 11
Study 1172599 — intervention group
Group type: EXPERIMENTAL
Intervention: oxyfedrin/beta‐acetyldigoxin tablets (ildamen¿‐Novodigal¿)
Number of subjects: 11
Study 1172599 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐acetyldigoxin liquid
Number of subjects: 11
Study 1172599 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐acetyldigoxin in alcoholic solution
Number of subjects: 11
Study 1172599 — intervention group
Group type: COMPARATOR
Intervention: digoxin solution
Number of subjects: 11
Study 1172599 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐acetyldigoxin tablets
Number of subjects: 11
Study 1172599 — intervention group
Group type: COMPARATOR
Intervention: digoxin tablets (Digacin¿)
Number of subjects: 11
Study 29559283 — intervention group
Group type: EXPERIMENTAL
Intervention: 74 Gy/37 fractions
Number of subjects: 346
Study 29559283 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy/20 fractions
Number of subjects: 346
Study 29559283 — intervention group
Group type: EXPERIMENTAL
Intervention: 57 Gy/19 fractions
Number of subjects: 346
Study 29559283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67
Number of subjects: 346
Study 27441461 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Number of subjects: 11
Study 27441461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26297500 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month hypocaloric diet (HCD)
Number of subjects: 17
Study 26297500 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and BMI-matched subjects)
Number of subjects: 17
Study 26297500 — intervention group
Group type: EXPERIMENTAL
Intervention: HCD
Number of subjects: 17
Study 23190425 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI (Edwards Sapien or CoreValve device)
Number of subjects: 35
Study 23190425 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI (Edwards Sapien device)
Number of subjects: 35
Study 23190425 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI (CoreValve device)
Number of subjects: 35
Study 23190425 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI (pre-TAVI EROA)
Number of subjects: 35
Study 23190425 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI (pre-TAVI MR index)
Number of subjects: 35
Study 22004614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria in infants (IPTi)
Number of subjects: 0
Study 20108513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexvix blue light cystoscopy (BLC)
Number of subjects: 20
Study 20108513 — intervention group
Group type: COMPARATOR
Intervention: Standard white light cystoscopy (WLC)
Number of subjects: 20
Study 16431398 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release diltiazem pellets
Number of subjects: 6
Study 16431398 — intervention group
Group type: COMPARATOR
Intervention: Herbesser SR
Number of subjects: 6
Study 12436805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) - ten sessions
Number of subjects: 108
Study 12436805 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine - 20 mg daily
Number of subjects: 108
Study 12436805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (CBT plus fluoxetine)
Number of subjects: 108
Study 12436805 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 108
Study 10359466 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal psychotherapy (8 weekly sessions)
Number of subjects: 110
Study 10359466 — intervention group
Group type: COMPARATOR
Intervention: Usual care from psychiatrist (Control)
Number of subjects: 110
Study 10359466 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal psychotherapy
Number of subjects: 110
Study 8537197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml of Mitomycin C (MMC)
Number of subjects: 89
Study 8537197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/ml of Mitomycin C (MMC)
Number of subjects: 89
Study 1743242 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal delivery system (TDS) with phasic release of glyceryl trinitrate (GTN)
Number of subjects: 8
Study 1743242 — intervention group
Group type: COMPARATOR
Intervention: Sublingual GTN 0.8 mg
Number of subjects: 8
Study 6750067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclacillin, administered in three divided doses (three times a day) for ten days
Number of subjects: 363
Study 6750067 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, similar regimen for ten days
Number of subjects: 363
Study 31859153 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training
Number of subjects: 40
Study 31859153 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training only
Number of subjects: 40
Study 31148988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek 2 g/day
Number of subjects: 12
Study 31148988 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide 5 mg once daily
Number of subjects: 12
Study 28277854 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 75 mg intravenous (IV)
Number of subjects: 0
Study 28277854 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneous (SC)
Number of subjects: 0
Study 28277854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28277854 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab groups (75 mg IV and 100 mg SC)
Number of subjects: 0
Study 26621118 — intervention group
Group type: EXPERIMENTAL
Intervention: XM17 (300 IU subcutaneous)
Number of subjects: 36
Study 26621118 — intervention group
Group type: COMPARATOR
Intervention: Gonal-f(®) (300 IU subcutaneous)
Number of subjects: 36
Study 26621118 — intervention group
Group type: EXPERIMENTAL
Intervention: XM17
Number of subjects: 36
Study 26621118 — intervention group
Group type: COMPARATOR
Intervention: Gonal-f(®)
Number of subjects: 36
Study 22989158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting in a chair for 2 hours postoperatively (group 1)
Number of subjects: 40
Study 22989158 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning for 2 hours postoperatively (group 2)
Number of subjects: 40
Study 22498923 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative video
Number of subjects: 59
Study 22498923 — intervention group
Group type: COMPARATOR
Intervention: Informational video
Number of subjects: 59
Study 19179915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar belt (BWG)
Number of subjects: 197
Study 17545139 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention (set of 10 videos, workbook, weekly telephone coaching sessions)
Number of subjects: 32
Study 17545139 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic education intervention (educational booklet and biweekly check-in telephone calls)
Number of subjects: 32
Study 15457551 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2b + ribavirin (treatment group = TG)
Number of subjects: 101
Study 15457551 — intervention group
Group type: COMPARATOR
Intervention: Old treatment control group (OTCG) with IFN-alpha2b
Number of subjects: 101
Study 15457551 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no treatment
Number of subjects: 101
Study 11466162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb) administered for 30 days
Number of subjects: 61
Study 11466162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9534633 — intervention group
Group type: EXPERIMENTAL
Intervention: Deeply anaesthetised group
Number of subjects: 66
Study 9534633 — intervention group
Group type: COMPARATOR
Intervention: Awake group
Number of subjects: 66
Study 9534633 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetised group
Number of subjects: 66
Study 7697239 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPA (10% lidocaine spray and 0.25% bupivocaine gargle)
Number of subjects: 6
Study 7697239 — intervention group
Group type: COMPARATOR
Intervention: Control (saline placebo)
Number of subjects: 6
Study 2689014 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 125 mg b.i.d.
Number of subjects: 36
Study 2689014 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 250 mg (microsize) b.i.d.
Number of subjects: 36
Study 1098216 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK)
Number of subjects: 0
Study 1098216 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 0
Study 1098216 — intervention group
Group type: COMPARATOR
Intervention: 12-hour Urokinase (12h-UK)
Number of subjects: 0
Study 31735564 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal voice
Number of subjects: 60
Study 31735564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no maternal voice)
Number of subjects: 60
Study 31366752 — intervention group
Group type: EXPERIMENTAL
Intervention: Life‐Trouble Inclusion Scale-based care planning tool
Number of subjects: 26
Study 31366752 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study 28982672 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release torsemide
Number of subjects: 10
Study 28982672 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release torsemide
Number of subjects: 10
Study 26447524 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized and supervised exercise program over 6 months
Number of subjects: 33
Study 26447524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 33
Study 22892141 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behaviour therapy (CBT) after psycho-education materials
Number of subjects: 21
Study 22892141 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education materials
Number of subjects: 21
Study 22892141 — intervention group
Group type: COMPARATOR
Intervention: Baseline waitlist
Number of subjects: 21
Study 21493672 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day)
Number of subjects: 106
Study 21493672 — intervention group
Group type: EXPERIMENTAL
Intervention: Late pubertal induction with ethinylestradiol (starting at age 14)
Number of subjects: 106
Study 21493672 — intervention group
Group type: COMPARATOR
Intervention: Oxandrolone alone, late induction alone, and oxandrolone plus late induction
Number of subjects: 106
Study 19621690 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g AzOAB: Azithromycin 500 mg twice daily for 6 days and Omeprazole 20 mg, Amoxicillin 1 g, Bismuth 240 mg all twice daily for 2 weeks
Number of subjects: 84
Study 19621690 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g AzOAB: Azithromycin 500 mg twice daily for 3 days and Omeprazole 20 mg, Amoxicillin 1 g, Bismuth 240 mg all twice daily for 1 week
Number of subjects: 84
Study 19621690 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g AzOAB: Azithromycin 250 mg twice daily for 3 days and Omeprazole 20 mg, Amoxicillin 1 g, Bismuth 240 mg all twice daily for 1 week
Number of subjects: 84
Study 16434269 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic harvest
Number of subjects: 54
Study 16434269 — intervention group
Group type: COMPARATOR
Intervention: Conventional harvest with cautery
Number of subjects: 54
Study 16434269 — intervention group
Group type: COMPARATOR
Intervention: Conventional harvest with harmonic scalpel
Number of subjects: 54
Study 15262041 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive intermittent hypoxia (15 sessions, 3-5 min hypoxic periods at 14-10% oxygen with 3-min normoxic intervals)
Number of subjects: 16
Study 15262041 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (control group, inhaled normoxic air)
Number of subjects: 16
Study 15262041 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive intermittent hypoxia
Number of subjects: 16
Study 12536729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 67
Study 12536729 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (UK)
Number of subjects: 67
Study 9292383 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback given to boys with ADHD after the first interaction.
Number of subjects: 60
Study 9292383 — intervention group
Group type: COMPARATOR
Intervention: Positive feedback given to comparison boys after the first interaction.
Number of subjects: 60
Study 8279244 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 40 micrograms.kg‐1
Number of subjects: 45
Study 8279244 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms.kg‐1
Number of subjects: 45